JP2011500774A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011500774A5 JP2011500774A5 JP2010530548A JP2010530548A JP2011500774A5 JP 2011500774 A5 JP2011500774 A5 JP 2011500774A5 JP 2010530548 A JP2010530548 A JP 2010530548A JP 2010530548 A JP2010530548 A JP 2010530548A JP 2011500774 A5 JP2011500774 A5 JP 2011500774A5
- Authority
- JP
- Japan
- Prior art keywords
- thieno
- morpholin
- indol
- ylmethyl
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000623 heterocyclic group Chemical group 0.000 claims description 19
- 229920006395 saturated elastomer Polymers 0.000 claims description 16
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 125000005842 heteroatom Chemical group 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 4
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims description 4
- 125000002837 carbocyclic group Chemical group 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 claims description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 2
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims description 2
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 125000004585 polycyclic heterocycle group Chemical group 0.000 claims description 2
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 2
- -1 fluoro-1H-indol-4-yl Chemical group 0.000 claims 24
- 150000001875 compounds Chemical class 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 208000012902 Nervous system disease Diseases 0.000 claims 3
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims 3
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims 3
- 208000036142 Viral infection Diseases 0.000 claims 3
- 230000002159 abnormal effect Effects 0.000 claims 3
- 230000006399 behavior Effects 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 230000003915 cell function Effects 0.000 claims 3
- 230000010261 cell growth Effects 0.000 claims 3
- 230000004064 dysfunction Effects 0.000 claims 3
- 230000002124 endocrine Effects 0.000 claims 3
- 208000026278 immune system disease Diseases 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 230000002503 metabolic effect Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 230000009385 viral infection Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- RBNBDIMXFJYDLQ-UHFFFAOYSA-N thieno[3,2-d]pyrimidine Chemical compound C1=NC=C2SC=CC2=N1 RBNBDIMXFJYDLQ-UHFFFAOYSA-N 0.000 claims 2
- AORBQLLXMHRCRJ-OAHLLOKOSA-N (8ar)-7-[[2-(5-fluoro-1h-indol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-5,6,8,8a-tetrahydro-1h-[1,3]oxazolo[3,4-a]pyrazin-3-one Chemical compound FC1=CC=C2NC=CC2=C1C(N=C1C=C(CN2C[C@H]3N(C(OC3)=O)CC2)SC1=1)=NC=1N1CCOCC1 AORBQLLXMHRCRJ-OAHLLOKOSA-N 0.000 claims 1
- DNGSYUQVIAWVFQ-HXUWFJFHSA-N (9ar)-2-[[2-(5-fluoro-1h-indol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-1,3,4,7,8,9a-hexahydropyrazino[1,2-a]pyrazine-6,9-dione Chemical compound FC1=CC=C2NC=CC2=C1C(N=C1C=C(CN2C[C@H]3N(C(CNC3=O)=O)CC2)SC1=1)=NC=1N1CCOCC1 DNGSYUQVIAWVFQ-HXUWFJFHSA-N 0.000 claims 1
- JSISTYTUHYTCID-QGZVFWFLSA-N (9ar)-8-[[2-(5-fluoro-1h-indol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-3,4,6,7,9,9a-hexahydro-1h-pyrazino[2,1-c][1,4]oxazine Chemical compound FC1=CC=C2NC=CC2=C1C(N=C1C=C(CN2C[C@@H]3COCCN3CC2)SC1=1)=NC=1N1CCOCC1 JSISTYTUHYTCID-QGZVFWFLSA-N 0.000 claims 1
- CYLZAJQKTXDJEO-MRXNPFEDSA-N (9ar)-8-[[2-(5-fluoro-1h-indol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-6,7,9,9a-tetrahydro-1h-pyrazino[2,1-c][1,4]oxazin-4-one Chemical compound FC1=CC=C2NC=CC2=C1C(N=C1C=C(CN2C[C@H]3N(C(COC3)=O)CC2)SC1=1)=NC=1N1CCOCC1 CYLZAJQKTXDJEO-MRXNPFEDSA-N 0.000 claims 1
- JSISTYTUHYTCID-KRWDZBQOSA-N (9as)-8-[[2-(5-fluoro-1h-indol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-3,4,6,7,9,9a-hexahydro-1h-pyrazino[2,1-c][1,4]oxazine Chemical compound FC1=CC=C2NC=CC2=C1C(N=C1C=C(CN2C[C@H]3COCCN3CC2)SC1=1)=NC=1N1CCOCC1 JSISTYTUHYTCID-KRWDZBQOSA-N 0.000 claims 1
- JFPVYRDYJSGEPF-UHFFFAOYSA-N 1-[1-[[2-(1h-indol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]piperidin-4-yl]azetidin-2-one Chemical compound O=C1CCN1C1CCN(CC=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=CNC=3C=CC=2)CC1 JFPVYRDYJSGEPF-UHFFFAOYSA-N 0.000 claims 1
- KFJHSPQDUYLNRI-UHFFFAOYSA-N 1-[1-[[2-(5-fluoro-1h-indol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]piperidin-4-yl]azetidin-2-one Chemical compound FC1=CC=C2NC=CC2=C1C(N=C1C=C(CN2CCC(CC2)N2C(CC2)=O)SC1=1)=NC=1N1CCOCC1 KFJHSPQDUYLNRI-UHFFFAOYSA-N 0.000 claims 1
- LPHQLNSWUVQCSA-UHFFFAOYSA-N 1-[1-[[2-(5-fluoro-1h-indol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]piperidin-4-yl]azetidin-3-ol Chemical compound C1C(O)CN1C1CCN(CC=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=CNC=3C=CC=2F)CC1 LPHQLNSWUVQCSA-UHFFFAOYSA-N 0.000 claims 1
- FRANXPLFPXBZAT-UHFFFAOYSA-N 1-[2-[[2-(5-fluoro-1h-indol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]ethanone Chemical compound C1C2CN(C(=O)C)CC2CN1CC(SC1=2)=CC1=NC(C=1C=3C=CNC=3C=CC=1F)=NC=2N1CCOCC1 FRANXPLFPXBZAT-UHFFFAOYSA-N 0.000 claims 1
- CJHGBUFGBANITH-UHFFFAOYSA-N 1-[2-[[2-(5-fluoro-1h-indol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-2,7-diazaspiro[3.5]nonan-7-yl]ethanone Chemical compound C1CN(C(=O)C)CCC11CN(CC=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=CNC=3C=CC=2F)C1 CJHGBUFGBANITH-UHFFFAOYSA-N 0.000 claims 1
- NVSSUWVGXFXIFP-UHFFFAOYSA-N 1-[[2-(5-fluoro-1h-indol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-n-methyl-n-(oxan-4-yl)piperidin-4-amine Chemical compound C1CN(CC=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=CNC=3C=CC=2F)CCC1N(C)C1CCOCC1 NVSSUWVGXFXIFP-UHFFFAOYSA-N 0.000 claims 1
- DRDPFMWRRRMZIR-UHFFFAOYSA-N 1-[[2-(5-fluoro-1h-indol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-n-methyl-n-(oxolan-3-yl)piperidin-4-amine Chemical compound C1CN(CC=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=CNC=3C=CC=2F)CCC1N(C)C1CCOC1 DRDPFMWRRRMZIR-UHFFFAOYSA-N 0.000 claims 1
- RKKKKOZHFZWVCC-UHFFFAOYSA-N 2-[[2-(5-fluoro-1h-indol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-2,7-diazaspiro[3.5]nonane-7-carboxamide Chemical compound C1CN(C(=O)N)CCC11CN(CC=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=CNC=3C=CC=2F)C1 RKKKKOZHFZWVCC-UHFFFAOYSA-N 0.000 claims 1
- YTKVTIGWSOFONQ-UHFFFAOYSA-N 2-[[2-(5-fluoro-1h-indol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-n,n-dimethyl-2,7-diazaspiro[3.5]nonane-7-carboxamide Chemical compound C1CN(C(=O)N(C)C)CCC11CN(CC=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=CNC=3C=CC=2F)C1 YTKVTIGWSOFONQ-UHFFFAOYSA-N 0.000 claims 1
- BCIMFQRMODOWFK-UHFFFAOYSA-N 4-[2-(1h-indol-4-yl)-6-[[4-(oxan-4-yl)piperazin-1-yl]methyl]thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C=1C2=NC(C=3C=4C=CNC=4C=CC=3)=NC(N3CCOCC3)=C2SC=1CN(CC1)CCN1C1CCOCC1 BCIMFQRMODOWFK-UHFFFAOYSA-N 0.000 claims 1
- BBAJVIVTBPZDOE-UHFFFAOYSA-N 4-[2-(1h-indol-4-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C1COCCN1C1=NC(C=2C=3C=CNC=3C=CC=2)=NC2=C1SC=C2 BBAJVIVTBPZDOE-UHFFFAOYSA-N 0.000 claims 1
- BBEODJZWWXZCSD-UHFFFAOYSA-N 4-[2-(5-fluoro-1h-indol-4-yl)-6-[(5-methylsulfonyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-2-yl)methyl]thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C1C2CN(S(=O)(=O)C)CC2CN1CC(SC1=2)=CC1=NC(C=1C=3C=CNC=3C=CC=1F)=NC=2N1CCOCC1 BBEODJZWWXZCSD-UHFFFAOYSA-N 0.000 claims 1
- IHQHYKUVUQXRGX-UHFFFAOYSA-N 4-[2-(5-fluoro-1h-indol-4-yl)-6-[(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)methyl]thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C1CN(C)CCC11CN(CC=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=CNC=3C=CC=2F)C1 IHQHYKUVUQXRGX-UHFFFAOYSA-N 0.000 claims 1
- YSESYAULARMLRW-UHFFFAOYSA-N 4-[2-(5-fluoro-1h-indol-4-yl)-6-[(7-methylsulfonyl-2,7-diazaspiro[3.5]nonan-2-yl)methyl]thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C1CN(S(=O)(=O)C)CCC11CN(CC=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=CNC=3C=CC=2F)C1 YSESYAULARMLRW-UHFFFAOYSA-N 0.000 claims 1
- DKBJWUPJJYNYQB-UHFFFAOYSA-N 4-[2-(5-fluoro-1h-indol-4-yl)-6-[[4-(2-methyloxolan-3-yl)piperazin-1-yl]methyl]thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound CC1OCCC1N1CCN(CC=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=CNC=3C=CC=2F)CC1 DKBJWUPJJYNYQB-UHFFFAOYSA-N 0.000 claims 1
- NRINFJWFORTBRE-UHFFFAOYSA-N 4-[2-(5-fluoro-1h-indol-4-yl)-6-[[4-(3-methoxyazetidin-1-yl)piperidin-1-yl]methyl]thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C1C(OC)CN1C1CCN(CC=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=CNC=3C=CC=2F)CC1 NRINFJWFORTBRE-UHFFFAOYSA-N 0.000 claims 1
- MOYRFCZNGONPFW-UHFFFAOYSA-N 4-[2-(5-fluoro-1h-indol-4-yl)-6-[[4-(oxolan-3-yl)piperazin-1-yl]methyl]thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound FC1=CC=C2NC=CC2=C1C(N=C1C=C(CN2CCN(CC2)C2COCC2)SC1=1)=NC=1N1CCOCC1 MOYRFCZNGONPFW-UHFFFAOYSA-N 0.000 claims 1
- LHOBSAWNQHVANO-UHFFFAOYSA-N 4-[6-(1,2,3,3a,4,6,7,7a-octahydropyrrolo[3,2-c]pyridin-5-ylmethyl)-2-(6-fluoro-1h-indol-4-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C=12C=CNC2=CC(F)=CC=1C(N=C1C=C(CN2CC3CCNC3CC2)SC1=1)=NC=1N1CCOCC1 LHOBSAWNQHVANO-UHFFFAOYSA-N 0.000 claims 1
- ICMMSJHJUDXLOT-UHFFFAOYSA-N 4-[6-(2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrol-5-ylmethyl)-2-(1h-indol-4-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C1C2CNCC2CN1CC(SC1=2)=CC1=NC(C=1C=3C=CNC=3C=CC=1)=NC=2N1CCOCC1 ICMMSJHJUDXLOT-UHFFFAOYSA-N 0.000 claims 1
- LMOVXGRXJGPEHZ-UHFFFAOYSA-N 4-[6-(2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrol-5-ylmethyl)-2-(5-fluoro-1h-indol-4-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound FC1=CC=C2NC=CC2=C1C(N=C1C=C(CN2CC3CNCC3C2)SC1=1)=NC=1N1CCOCC1 LMOVXGRXJGPEHZ-UHFFFAOYSA-N 0.000 claims 1
- WBRUMMGTUARXRA-UHFFFAOYSA-N 4-[6-(2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrol-5-ylmethyl)-2-(6-fluoro-1h-indol-4-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C=12C=CNC2=CC(F)=CC=1C(N=C1C=C(CN2CC3CNCC3C2)SC1=1)=NC=1N1CCOCC1 WBRUMMGTUARXRA-UHFFFAOYSA-N 0.000 claims 1
- MFLJGTDDTWCCRW-UHFFFAOYSA-N 4-[6-(2,7-diazaspiro[3.5]nonan-2-ylmethyl)-2-(1h-indol-4-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C=1C2=NC(C=3C=4C=CNC=4C=CC=3)=NC(N3CCOCC3)=C2SC=1CN(C1)CC21CCNCC2 MFLJGTDDTWCCRW-UHFFFAOYSA-N 0.000 claims 1
- PUEOEISBMONAAL-UHFFFAOYSA-N 4-[6-(3,8-diazabicyclo[3.2.1]octan-3-ylmethyl)-2-(5-fluoro-1h-indol-4-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound FC1=CC=C2NC=CC2=C1C(N=C1C=C(CN2CC3CCC(N3)C2)SC1=1)=NC=1N1CCOCC1 PUEOEISBMONAAL-UHFFFAOYSA-N 0.000 claims 1
- UHERRTATLBUVOR-UHFFFAOYSA-N 4-[6-(3,8-diazabicyclo[3.2.1]octan-3-ylmethyl)-2-(6-fluoro-1h-indol-4-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C=12C=CNC2=CC(F)=CC=1C(N=C1C=C(CN2CC3CCC(N3)C2)SC1=1)=NC=1N1CCOCC1 UHERRTATLBUVOR-UHFFFAOYSA-N 0.000 claims 1
- UUWAWKQDBCECJX-UHFFFAOYSA-N 4-[6-(3,8-diazabicyclo[3.2.1]octan-8-ylmethyl)-2-(6-fluoro-1h-indol-4-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C=12C=CNC2=CC(F)=CC=1C(N=C1C=C(CN2C3CCC2CNC3)SC1=1)=NC=1N1CCOCC1 UUWAWKQDBCECJX-UHFFFAOYSA-N 0.000 claims 1
- XJEQMPLBTKKEJK-UHFFFAOYSA-N 4-[6-(6,8-dihydro-5h-[1,2,4]triazolo[4,3-a]pyrazin-7-ylmethyl)-2-(5-fluoro-1h-indol-4-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound FC1=CC=C2NC=CC2=C1C(N=C1C=C(CN2CC3=NN=CN3CC2)SC1=1)=NC=1N1CCOCC1 XJEQMPLBTKKEJK-UHFFFAOYSA-N 0.000 claims 1
- CSKKXLKCXMQSGQ-UHFFFAOYSA-N 4-[6-(6,8-dihydro-5h-imidazo[1,2-a]pyrazin-7-ylmethyl)-2-(6-fluoro-1h-indol-4-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C=12C=CNC2=CC(F)=CC=1C(N=C1C=C(CN2CC3=NC=CN3CC2)SC1=1)=NC=1N1CCOCC1 CSKKXLKCXMQSGQ-UHFFFAOYSA-N 0.000 claims 1
- NJXPCLZGJUNUMI-UHFFFAOYSA-N 4-[6-[(4-cyclopropylpiperazin-1-yl)methyl]-2-(5-fluoro-1h-indol-4-yl)thieno[2,3-d]pyrimidin-4-yl]morpholine Chemical compound FC1=CC=C2NC=CC2=C1C(N=C1SC(CN2CCN(CC2)C2CC2)=CC1=1)=NC=1N1CCOCC1 NJXPCLZGJUNUMI-UHFFFAOYSA-N 0.000 claims 1
- LBASZWYONKCNRK-UHFFFAOYSA-N 4-[6-[(4-cyclopropylpiperazin-1-yl)methyl]-2-(5-fluoro-1h-indol-4-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound FC1=CC=C2NC=CC2=C1C(N=C1C=C(CN2CCN(CC2)C2CC2)SC1=1)=NC=1N1CCOCC1 LBASZWYONKCNRK-UHFFFAOYSA-N 0.000 claims 1
- VEGWLOGQHCZZSX-UHFFFAOYSA-N 4-[6-[(4-cyclopropylpiperazin-1-yl)methyl]-2-(6-fluoro-1h-indol-4-yl)thieno[2,3-d]pyrimidin-4-yl]morpholine Chemical compound C=12C=CNC2=CC(F)=CC=1C(N=C1SC(CN2CCN(CC2)C2CC2)=CC1=1)=NC=1N1CCOCC1 VEGWLOGQHCZZSX-UHFFFAOYSA-N 0.000 claims 1
- IOWFZIDMJRMFHV-UHFFFAOYSA-N 4-[6-[(4-cyclopropylpiperazin-1-yl)methyl]-2-(6-fluoro-1h-indol-4-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C=12C=CNC2=CC(F)=CC=1C(N=C1C=C(CN2CCN(CC2)C2CC2)SC1=1)=NC=1N1CCOCC1 IOWFZIDMJRMFHV-UHFFFAOYSA-N 0.000 claims 1
- ZZGQDELLXQBUEV-UHFFFAOYSA-N 4-[6-[(4-cyclopropylpiperazin-1-yl)methyl]-2-(6-methyl-1h-indol-4-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C=12C=CNC2=CC(C)=CC=1C(N=C1C=C(CN2CCN(CC2)C2CC2)SC1=1)=NC=1N1CCOCC1 ZZGQDELLXQBUEV-UHFFFAOYSA-N 0.000 claims 1
- RTAQXQLGVFXPPV-UHFFFAOYSA-N 4-[6-[(4-cyclopropylpiperazin-1-yl)methyl]-2-(6-methylsulfonyl-1h-indol-4-yl)thieno[2,3-d]pyrimidin-4-yl]morpholine Chemical compound C=12C=CNC2=CC(S(=O)(=O)C)=CC=1C(N=C1SC(CN2CCN(CC2)C2CC2)=CC1=1)=NC=1N1CCOCC1 RTAQXQLGVFXPPV-UHFFFAOYSA-N 0.000 claims 1
- AKEADGLLPYZKBW-UHFFFAOYSA-N 4-[6-[(4-cyclopropylpiperazin-1-yl)methyl]-2-(6-methylsulfonyl-1h-indol-4-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C=12C=CNC2=CC(S(=O)(=O)C)=CC=1C(N=C1C=C(CN2CCN(CC2)C2CC2)SC1=1)=NC=1N1CCOCC1 AKEADGLLPYZKBW-UHFFFAOYSA-N 0.000 claims 1
- JUABIBUTGNRXHW-UHFFFAOYSA-N 4-[6-[(4-cyclopropylpiperazin-1-yl)methyl]-2-[2-(trifluoromethyl)-1h-indol-4-yl]thieno[2,3-d]pyrimidin-4-yl]morpholine Chemical compound C1=CC=C2NC(C(F)(F)F)=CC2=C1C(N=C1SC(CN2CCN(CC2)C2CC2)=CC1=1)=NC=1N1CCOCC1 JUABIBUTGNRXHW-UHFFFAOYSA-N 0.000 claims 1
- WPPOOXLXDXPPFT-UHFFFAOYSA-N 4-[6-[(4-cyclopropylpiperazin-1-yl)methyl]-2-[2-(trifluoromethyl)-1h-indol-4-yl]thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C1=CC=C2NC(C(F)(F)F)=CC2=C1C(N=C1C=C(CN2CCN(CC2)C2CC2)SC1=1)=NC=1N1CCOCC1 WPPOOXLXDXPPFT-UHFFFAOYSA-N 0.000 claims 1
- YSZUYOALYPPOFG-UHFFFAOYSA-N 4-[6-[(4-cyclopropylpiperazin-1-yl)methyl]-2-[6-(trifluoromethyl)-1h-indol-4-yl]thieno[2,3-d]pyrimidin-4-yl]morpholine Chemical compound C=12C=CNC2=CC(C(F)(F)F)=CC=1C(N=C1SC(CN2CCN(CC2)C2CC2)=CC1=1)=NC=1N1CCOCC1 YSZUYOALYPPOFG-UHFFFAOYSA-N 0.000 claims 1
- PEKKKVSOTKLAAN-UHFFFAOYSA-N 4-[6-[(4-cyclopropylpiperazin-1-yl)methyl]-2-[6-(trifluoromethyl)-1h-indol-4-yl]thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C=12C=CNC2=CC(C(F)(F)F)=CC=1C(N=C1C=C(CN2CCN(CC2)C2CC2)SC1=1)=NC=1N1CCOCC1 PEKKKVSOTKLAAN-UHFFFAOYSA-N 0.000 claims 1
- AHEBDWYSGRPGHI-UHFFFAOYSA-N 4-[6-[(4-cyclopropylpiperazin-1-yl)methyl]-4-morpholin-4-ylthieno[2,3-d]pyrimidin-2-yl]-1h-indole-2-carbonitrile Chemical compound C1=CC=C2NC(C#N)=CC2=C1C(N=C1SC(CN2CCN(CC2)C2CC2)=CC1=1)=NC=1N1CCOCC1 AHEBDWYSGRPGHI-UHFFFAOYSA-N 0.000 claims 1
- UJMXSIHZTSRSQD-UHFFFAOYSA-N 4-[6-[(4-cyclopropylpiperazin-1-yl)methyl]-4-morpholin-4-ylthieno[2,3-d]pyrimidin-2-yl]-1h-indole-6-carbonitrile Chemical compound C=12C=CNC2=CC(C#N)=CC=1C(N=C1SC(CN2CCN(CC2)C2CC2)=CC1=1)=NC=1N1CCOCC1 UJMXSIHZTSRSQD-UHFFFAOYSA-N 0.000 claims 1
- HRMWAVIAROSMOA-UHFFFAOYSA-N 4-[6-[(4-cyclopropylpiperazin-1-yl)methyl]-4-morpholin-4-ylthieno[2,3-d]pyrimidin-2-yl]-1h-indole-6-carboxamide Chemical compound C=12C=CNC2=CC(C(=O)N)=CC=1C(N=C1SC(CN2CCN(CC2)C2CC2)=CC1=1)=NC=1N1CCOCC1 HRMWAVIAROSMOA-UHFFFAOYSA-N 0.000 claims 1
- VIZWYWZPKFSJAJ-UHFFFAOYSA-N 4-[6-[(4-cyclopropylpiperazin-1-yl)methyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-2-yl]-1h-indole-6-carbonitrile Chemical compound C=12C=CNC2=CC(C#N)=CC=1C(N=C1C=C(CN2CCN(CC2)C2CC2)SC1=1)=NC=1N1CCOCC1 VIZWYWZPKFSJAJ-UHFFFAOYSA-N 0.000 claims 1
- YYBKUAJNLGPBAM-UHFFFAOYSA-N 4-[6-[(4-cyclopropylpiperazin-1-yl)methyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-2-yl]-1h-indole-6-carboxamide Chemical compound C=12C=CNC2=CC(C(=O)N)=CC=1C(N=C1C=C(CN2CCN(CC2)C2CC2)SC1=1)=NC=1N1CCOCC1 YYBKUAJNLGPBAM-UHFFFAOYSA-N 0.000 claims 1
- JZCYWFJQZXENAY-HOTGVXAUSA-N 4-[6-[[(1s,5s)-3,6-diazabicyclo[3.1.1]heptan-6-yl]methyl]-2-(6-fluoro-1h-indol-4-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound N1([C@@]2([H])C[C@]1(CNC2)[H])CC(SC1=2)=CC1=NC(C=1C=3C=CNC=3C=C(F)C=1)=NC=2N1CCOCC1 JZCYWFJQZXENAY-HOTGVXAUSA-N 0.000 claims 1
- LHOBSAWNQHVANO-IERDGZPVSA-N 4-[6-[[(3ar,7as)-1,2,3,3a,4,6,7,7a-octahydropyrrolo[3,2-c]pyridin-5-yl]methyl]-2-(6-fluoro-1h-indol-4-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C=12C=CNC2=CC(F)=CC=1C(N=C1C=C(CN2C[C@H]3CCN[C@H]3CC2)SC1=1)=NC=1N1CCOCC1 LHOBSAWNQHVANO-IERDGZPVSA-N 0.000 claims 1
- LHOBSAWNQHVANO-HRAATJIYSA-N 4-[6-[[(3as,7ar)-1,2,3,3a,4,6,7,7a-octahydropyrrolo[3,2-c]pyridin-5-yl]methyl]-2-(6-fluoro-1h-indol-4-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C=12C=CNC2=CC(F)=CC=1C(N=C1C=C(CN2C[C@@H]3CCN[C@@H]3CC2)SC1=1)=NC=1N1CCOCC1 LHOBSAWNQHVANO-HRAATJIYSA-N 0.000 claims 1
- JWOQPCQKIYZUJT-OFNKIYASSA-N 4-[6-[[(3r,4s)-4-(azetidin-1-yl)-3-fluoropiperidin-1-yl]methyl]-2-(5-fluoro-1h-indol-4-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C([C@H]([C@H](CC1)N2CCC2)F)N1CC(SC1=2)=CC1=NC(C=1C=3C=CNC=3C=CC=1F)=NC=2N1CCOCC1 JWOQPCQKIYZUJT-OFNKIYASSA-N 0.000 claims 1
- FNTSIORUDWQAAI-GOSISDBHSA-N 4-[6-[[(8ar)-3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-2-yl]methyl]-2-(6-fluoro-1h-indol-4-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C=12C=CNC2=CC(F)=CC=1C(N=C1C=C(CN2C[C@H]3CCCN3CC2)SC1=1)=NC=1N1CCOCC1 FNTSIORUDWQAAI-GOSISDBHSA-N 0.000 claims 1
- ZTHAIHPGDWAZCZ-SFHVURJKSA-N 4-[6-[[(8as)-3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-2-yl]methyl]-2-(1h-indol-4-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C([C@@H]1CCCN1CC1)N1CC(SC1=2)=CC1=NC(C=1C=3C=CNC=3C=CC=1)=NC=2N1CCOCC1 ZTHAIHPGDWAZCZ-SFHVURJKSA-N 0.000 claims 1
- PHPAVKODRBBLPJ-KRWDZBQOSA-N 4-[6-[[(8as)-3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-2-yl]methyl]-2-(5-fluoro-1h-indol-4-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound FC1=CC=C2NC=CC2=C1C(N=C1C=C(CN2C[C@@H]3CCCN3CC2)SC1=1)=NC=1N1CCOCC1 PHPAVKODRBBLPJ-KRWDZBQOSA-N 0.000 claims 1
- FNTSIORUDWQAAI-SFHVURJKSA-N 4-[6-[[(8as)-3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-2-yl]methyl]-2-(6-fluoro-1h-indol-4-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C=12C=CNC2=CC(F)=CC=1C(N=C1C=C(CN2C[C@@H]3CCCN3CC2)SC1=1)=NC=1N1CCOCC1 FNTSIORUDWQAAI-SFHVURJKSA-N 0.000 claims 1
- JREWMYMRYPUDFE-SFHVURJKSA-N 4-[6-[[(8as)-3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-2-yl]methyl]-2-(6-methylsulfonyl-1h-indol-4-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C=12C=CNC2=CC(S(=O)(=O)C)=CC=1C(N=C1C=C(CN2C[C@@H]3CCCN3CC2)SC1=1)=NC=1N1CCOCC1 JREWMYMRYPUDFE-SFHVURJKSA-N 0.000 claims 1
- MBQZJMNFHXSLSJ-UHFFFAOYSA-N 4-[6-[[4-(3,3-difluoroazetidin-1-yl)piperidin-1-yl]methyl]-2-(5-fluoro-1h-indol-4-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound FC1=CC=C2NC=CC2=C1C(N=C1C=C(CN2CCC(CC2)N2CC(F)(F)C2)SC1=1)=NC=1N1CCOCC1 MBQZJMNFHXSLSJ-UHFFFAOYSA-N 0.000 claims 1
- MAURCMYQKJGNKL-UHFFFAOYSA-N 4-[6-[[4-(3-fluoroazetidin-1-yl)piperidin-1-yl]methyl]-2-(1h-indol-4-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C1C(F)CN1C1CCN(CC=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=CNC=3C=CC=2)CC1 MAURCMYQKJGNKL-UHFFFAOYSA-N 0.000 claims 1
- ZGGKCESONORMNW-UHFFFAOYSA-N 4-[6-[[4-(3-fluoroazetidin-1-yl)piperidin-1-yl]methyl]-2-(5-fluoro-1h-indol-4-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C1C(F)CN1C1CCN(CC=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=CNC=3C=CC=2F)CC1 ZGGKCESONORMNW-UHFFFAOYSA-N 0.000 claims 1
- UXHGGXWQQDXOSL-UHFFFAOYSA-N 4-[6-[[4-(azetidin-1-yl)piperidin-1-yl]methyl]-2-(1h-indol-4-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C=1C2=NC(C=3C=4C=CNC=4C=CC=3)=NC(N3CCOCC3)=C2SC=1CN(CC1)CCC1N1CCC1 UXHGGXWQQDXOSL-UHFFFAOYSA-N 0.000 claims 1
- DVBFBQAHEHREEC-UHFFFAOYSA-N 4-[6-[[4-(azetidin-1-yl)piperidin-1-yl]methyl]-2-(5-fluoro-1h-indol-4-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound FC1=CC=C2NC=CC2=C1C(N=C1C=C(CN2CCC(CC2)N2CCC2)SC1=1)=NC=1N1CCOCC1 DVBFBQAHEHREEC-UHFFFAOYSA-N 0.000 claims 1
- YNTNHURYSUBGEK-UHFFFAOYSA-N 4-[6-[[4-(azetidin-1-yl)piperidin-1-yl]methyl]-2-(6-fluoro-1h-indol-4-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C=12C=CNC2=CC(F)=CC=1C(N=C1C=C(CN2CCC(CC2)N2CCC2)SC1=1)=NC=1N1CCOCC1 YNTNHURYSUBGEK-UHFFFAOYSA-N 0.000 claims 1
- OQGUKGDCJPVVSB-UHFFFAOYSA-N 4-[6-[[4-(azetidin-1-yl)piperidin-1-yl]methyl]-2-(6-methylsulfonyl-1h-indol-4-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C=12C=CNC2=CC(S(=O)(=O)C)=CC=1C(N=C1C=C(CN2CCC(CC2)N2CCC2)SC1=1)=NC=1N1CCOCC1 OQGUKGDCJPVVSB-UHFFFAOYSA-N 0.000 claims 1
- HWFUVMRHDSIYDQ-UHFFFAOYSA-N 4-[[2-(5-fluoro-1h-indol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-1-(oxan-4-yl)piperazin-2-one Chemical compound FC1=CC=C2NC=CC2=C1C(N=C1C=C(CN2CC(=O)N(C3CCOCC3)CC2)SC1=1)=NC=1N1CCOCC1 HWFUVMRHDSIYDQ-UHFFFAOYSA-N 0.000 claims 1
- VBROLTDPOWFKTL-UHFFFAOYSA-N 4-[[2-(5-fluoro-1h-indol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-1-oxa-4,9-diazaspiro[5.5]undecane Chemical compound FC1=CC=C2NC=CC2=C1C(N=C1C=C(CN2CC3(CCNCC3)OCC2)SC1=1)=NC=1N1CCOCC1 VBROLTDPOWFKTL-UHFFFAOYSA-N 0.000 claims 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- XCYQDPCVXAVMPC-UHFFFAOYSA-N 7-[[2-(5-fluoro-1h-indol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-2,7-diazaspiro[3.5]nonan-3-one Chemical compound FC1=CC=C2NC=CC2=C1C(N=C1C=C(CN2CCC3(C(NC3)=O)CC2)SC1=1)=NC=1N1CCOCC1 XCYQDPCVXAVMPC-UHFFFAOYSA-N 0.000 claims 1
- SPKFNHXDYBKJRQ-UHFFFAOYSA-N 7-[[2-(5-fluoro-1h-indol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-3-oxa-7,9-diazabicyclo[3.3.1]nonane Chemical compound FC1=CC=C2NC=CC2=C1C(N=C1C=C(CN2CC3COCC(N3)C2)SC1=1)=NC=1N1CCOCC1 SPKFNHXDYBKJRQ-UHFFFAOYSA-N 0.000 claims 1
- JSISTYTUHYTCID-UHFFFAOYSA-N 8-[[2-(5-fluoro-1h-indol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-3,4,6,7,9,9a-hexahydro-1h-pyrazino[2,1-c][1,4]oxazine Chemical compound FC1=CC=C2NC=CC2=C1C(N=C1C=C(CN2CC3COCCN3CC2)SC1=1)=NC=1N1CCOCC1 JSISTYTUHYTCID-UHFFFAOYSA-N 0.000 claims 1
- LISQRGKRBGUTAJ-UHFFFAOYSA-N 9-[[2-(5-fluoro-1h-indol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-1-oxa-4,9-diazaspiro[5.5]undecane Chemical compound FC1=CC=C2NC=CC2=C1C(N=C1C=C(CN2CCC3(CC2)OCCNC3)SC1=1)=NC=1N1CCOCC1 LISQRGKRBGUTAJ-UHFFFAOYSA-N 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- UZHKFZLMEWZCPD-MHECFPHRSA-N [(3R,4R)-4-(azetidin-1-yl)-1-[[2-(5-fluoro-1H-indol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]piperidin-3-yl]methanol Chemical compound C([C@H]([C@@H](CC1)N2CCC2)CO)N1CC(SC1=2)=CC1=NC(C=1C=3C=CNC=3C=CC=1F)=NC=2N1CCOCC1 UZHKFZLMEWZCPD-MHECFPHRSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 1
- YUEAEYBBCIZGSI-UHFFFAOYSA-N methyl 2-[[2-(5-fluoro-1h-indol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-2,7-diazaspiro[3.5]nonane-7-carboxylate Chemical compound C1CN(C(=O)OC)CCC11CN(CC=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=CNC=3C=CC=2F)C1 YUEAEYBBCIZGSI-UHFFFAOYSA-N 0.000 claims 1
- VZRWJMZZHDOBIO-UHFFFAOYSA-N n,n-dimethyl-1h-pyrrole-2-carboxamide Chemical compound CN(C)C(=O)C1=CC=CN1 VZRWJMZZHDOBIO-UHFFFAOYSA-N 0.000 claims 1
- IIYVBSCXDLYPMU-UHFFFAOYSA-N n-(cyclopropylmethyl)-1-[[2-(5-fluoro-1h-indol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]piperidin-4-amine Chemical compound FC1=CC=C2NC=CC2=C1C(N=C1C=C(CN2CCC(CC2)NCC2CC2)SC1=1)=NC=1N1CCOCC1 IIYVBSCXDLYPMU-UHFFFAOYSA-N 0.000 claims 1
- PFJSWBUIYQHLKB-UHFFFAOYSA-N n-(cyclopropylmethyl)-1-[[2-(6-fluoro-1h-indol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]piperidin-4-amine Chemical compound C=12C=CNC2=CC(F)=CC=1C(N=C1C=C(CN2CCC(CC2)NCC2CC2)SC1=1)=NC=1N1CCOCC1 PFJSWBUIYQHLKB-UHFFFAOYSA-N 0.000 claims 1
- MSSGLPQBDPKFMV-UHFFFAOYSA-N n-cyclobutyl-1-[[2-(5-fluoro-1h-indol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]-n-methylpiperidin-4-amine Chemical compound C1CN(CC=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=CNC=3C=CC=2F)CCC1N(C)C1CCC1 MSSGLPQBDPKFMV-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0721095.8 | 2007-10-26 | ||
| GBGB0721095.8A GB0721095D0 (en) | 2007-10-26 | 2007-10-26 | Pharmaceutical compounds |
| PCT/GB2008/003621 WO2009053715A1 (en) | 2007-10-26 | 2008-10-27 | Thienopyrimidiene derivatives as pi3k inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011500774A JP2011500774A (ja) | 2011-01-06 |
| JP2011500774A5 true JP2011500774A5 (enExample) | 2011-12-15 |
| JP5675360B2 JP5675360B2 (ja) | 2015-02-25 |
Family
ID=38830047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010530548A Expired - Fee Related JP5675360B2 (ja) | 2007-10-26 | 2008-10-27 | Ｐｉ３ｋ阻害剤としてのチエノピリミジエン誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8293735B2 (enExample) |
| EP (1) | EP2205610B1 (enExample) |
| JP (1) | JP5675360B2 (enExample) |
| CN (1) | CN101868464B (enExample) |
| CA (1) | CA2701276A1 (enExample) |
| ES (1) | ES2442501T3 (enExample) |
| GB (1) | GB0721095D0 (enExample) |
| WO (1) | WO2009053715A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| AU2006272555B2 (en) | 2005-07-25 | 2012-03-08 | Aptevo Research And Development Llc | B-cell reduction using CD37-specific and CD20-specific binding molecules |
| CN105837690A (zh) | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| WO2009055730A1 (en) | 2007-10-25 | 2009-04-30 | Genentech, Inc. | Process for making thienopyrimidine compounds |
| US7820665B2 (en) | 2007-12-19 | 2010-10-26 | Amgen Inc. | Imidazopyridazine inhibitors of PI3 kinase for cancer treatment |
| NZ603059A (en) | 2008-04-11 | 2014-07-25 | Emergent Product Dev Seattle | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
| TWI378933B (en) | 2008-10-14 | 2012-12-11 | Daiichi Sankyo Co Ltd | Morpholinopurine derivatives |
| MX2011012520A (es) | 2009-05-27 | 2011-12-12 | Hoffmann La Roche | Compuestos inhibidores de pi3k de pirimidina biciclicos selectivos para p110 delta y metodos de uso de los mismos. |
| SG182247A1 (en) * | 2009-05-27 | 2012-08-30 | Hoffmann La Roche | Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use |
| GB201004200D0 (en) * | 2010-03-15 | 2010-04-28 | Univ Basel | Spirocyclic compounds and their use as therapeutic agents and diagnostic probes |
| WO2011159726A2 (en) | 2010-06-14 | 2011-12-22 | The Scripps Research Institute | Reprogramming of cells to a new fate |
| EA026134B1 (ru) | 2010-12-16 | 2017-03-31 | Ф. Хоффманн-Ля Рош Аг | Трициклические ингибиторы pi3k и способы их применения |
| ES2464598T3 (es) | 2011-07-22 | 2014-06-03 | Université Joseph Fourier | Nuevos derivados bis-indólicos, procedimiento para su preparación, y sus utilizaciones como fármaco |
| CN104350144B (zh) | 2012-05-23 | 2017-08-04 | 弗·哈夫曼-拉罗切有限公司 | 获得和使用内胚层和肝细胞的组合物和方法 |
| EP2890698B1 (en) * | 2012-08-30 | 2017-03-01 | F. Hoffmann-La Roche AG | Dioxino- and oxazin-[2,3-d]pyrimidine pi3k inhibitor compounds and methods of use |
| GB201402431D0 (en) * | 2014-02-12 | 2014-03-26 | Karus Therapeutics Ltd | Compounds |
| HK1251480A1 (zh) | 2015-09-21 | 2019-02-01 | Aptevo Research And Development Llc | Cd3结合多肽 |
| US10591000B2 (en) * | 2016-05-24 | 2020-03-17 | Means Industries, Inc. | One-way clutch assembly and coupling member for therein wherein locking member dynamics with respect to strut laydown speed are enhanced |
| TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| US12139491B2 (en) * | 2018-12-27 | 2024-11-12 | Holosmedic | Diketopiperazine derivatives as calcium ATPase inhibitor for enhancing anticancer activity |
| KR102338609B1 (ko) * | 2019-05-20 | 2021-12-14 | 보령제약 주식회사 | 피리도-피리미딘 화합물 및 이를 유효성분으로 포함하는 pi3k 관련 질환의 예방 또는 치료용 약학적 조성물 |
| WO2020234103A1 (en) | 2019-05-21 | 2020-11-26 | Bayer Aktiengesellschaft | Identification and use of kras inhibitors |
| WO2020243459A1 (en) * | 2019-05-31 | 2020-12-03 | Ideaya Biosciences, Inc. | Thiadiazolyl derivatives as dna polymerase theta inhibitors |
| IL292631A (en) * | 2019-10-31 | 2022-07-01 | Holosmedic | Novel compound and pharmaceutical composition for prevention or treatment of cancer comprising same |
| CN112920199B (zh) * | 2020-06-02 | 2023-02-03 | 四川大学 | 一种哌嗪酮取代物或其衍生物及其制备方法和应用、药物组合物 |
| US20250214980A1 (en) | 2022-03-14 | 2025-07-03 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| WO2026120044A1 (en) | 2024-12-04 | 2026-06-11 | Astrazeneca Ab | Smarca2 degraders and uses thereof |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1470356A1 (de) * | 1964-01-15 | 1970-04-30 | Thomae Gmbh Dr K | Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung |
| BE754606A (fr) * | 1969-08-08 | 1971-02-08 | Thomae Gmbh Dr K | Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication |
| BE759493A (fr) * | 1969-11-26 | 1971-05-25 | Thomae Gmbh Dr K | Nouvelles 2-(5-nitro-2-furyl)-thieno(3,2-d) pyrimidines et procedes pour les fabriquer |
| US3763156A (en) * | 1970-01-28 | 1973-10-02 | Boehringer Sohn Ingelheim | 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines |
| RO62428A (fr) | 1971-05-04 | 1978-01-15 | Thomae Gmbh Dr K | Procede pour la preparation des thyeno-(3,2-d)-pyrimidines |
| CH592668A5 (enExample) * | 1973-10-02 | 1977-10-31 | Delalande Sa | |
| GB1570494A (en) * | 1975-11-28 | 1980-07-02 | Ici Ltd | Thienopyrimidine derivatives and their use as pesticides |
| ZA782648B (en) * | 1977-05-23 | 1979-06-27 | Ici Australia Ltd | The prevention,control or eradication of infestations of ixodid ticks |
| DE69943144D1 (de) * | 1998-03-31 | 2011-03-03 | Kyowa Hakko Kirin Co Ltd | Stickstoffenthaltende heterocyclische verbindungen |
| US6232320B1 (en) * | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| AU5261001A (en) | 2000-04-27 | 2001-11-12 | Imperial Cancer Research Technology Ltd | Condensed heteroaryl derivatives |
| US6608053B2 (en) * | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| US20020156601A1 (en) * | 2001-04-19 | 2002-10-24 | Tu Kevin Hsiaohsu | Event monitoring and detection system |
| WO2004017950A2 (en) | 2002-08-22 | 2004-03-04 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
| ES2217956B1 (es) | 2003-01-23 | 2006-04-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo. |
| GB0423653D0 (en) * | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
| GB0520657D0 (en) | 2005-10-11 | 2005-11-16 | Ludwig Inst Cancer Res | Pharmaceutical compounds |
| AU2007243466B2 (en) * | 2006-04-26 | 2012-01-19 | F. Hoffmann-La Roche Ag | Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them |
| KR20090021155A (ko) * | 2006-04-26 | 2009-02-27 | 에프. 호프만-라 로슈 아게 | Ｐｉ3ｋ 억제제로서의 피리미딘 유도체 |
| KR101533461B1 (ko) * | 2006-04-26 | 2015-07-02 | 에프. 호프만-라 로슈 아게 | Ｐｉ３ｋ저해제로 유용한 티에노［3,2-ｄ］피리미딘 유도체 |
| PL2041139T3 (pl) * | 2006-04-26 | 2012-05-31 | Hoffmann La Roche | Związki farmaceutyczne |
| GB0608820D0 (en) * | 2006-05-04 | 2006-06-14 | Piramed Ltd | Pharmaceutical compounds |
| PE20081679A1 (es) * | 2006-12-07 | 2008-12-18 | Hoffmann La Roche | Compuestos del inhibidor de fosfoinositida 3-cinasa y metodos de uso |
| CA2671845C (en) * | 2006-12-07 | 2015-03-24 | Genentech, Inc. | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
| BRPI0816769A2 (pt) * | 2007-09-12 | 2016-11-29 | Hoffmann La Roche | combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso |
| CN101932587A (zh) * | 2007-09-24 | 2010-12-29 | 吉宁特有限公司 | 噻唑并嘧啶pi3k抑制剂化合物及使用方法 |
| WO2009055730A1 (en) * | 2007-10-25 | 2009-04-30 | Genentech, Inc. | Process for making thienopyrimidine compounds |
| JP5638955B2 (ja) | 2007-10-26 | 2014-12-10 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｐｉ３キナーゼ阻害剤として有用なプリン誘導体 |
| ES2533788T3 (es) * | 2008-05-30 | 2015-04-14 | Genentech, Inc. | Compuestos inhibidores de PI3K de tipo purina y métodos de uso |
| MX2011012520A (es) * | 2009-05-27 | 2011-12-12 | Hoffmann La Roche | Compuestos inhibidores de pi3k de pirimidina biciclicos selectivos para p110 delta y metodos de uso de los mismos. |
| SG182247A1 (en) * | 2009-05-27 | 2012-08-30 | Hoffmann La Roche | Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use |
-
2007
- 2007-10-26 GB GBGB0721095.8A patent/GB0721095D0/en not_active Ceased
-
2008
- 2008-10-27 WO PCT/GB2008/003621 patent/WO2009053715A1/en not_active Ceased
- 2008-10-27 ES ES08842778.6T patent/ES2442501T3/es active Active
- 2008-10-27 CN CN2008801126921A patent/CN101868464B/zh not_active Expired - Fee Related
- 2008-10-27 EP EP08842778.6A patent/EP2205610B1/en not_active Not-in-force
- 2008-10-27 US US12/739,435 patent/US8293735B2/en not_active Expired - Fee Related
- 2008-10-27 CA CA2701276A patent/CA2701276A1/en not_active Abandoned
- 2008-10-27 JP JP2010530548A patent/JP5675360B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10934302B1 (en) | SHP2 phosphatase inhibitors and methods of use thereof | |
| CN117651700A (zh) | 2-氨基苯并噻唑化合物及使用方法 | |
| JP2015504057A5 (enExample) | ||
| KR101787680B1 (ko) | 키나아제 억제제 및 이의 용도 | |
| JP2024517693A5 (enExample) | ||
| JP2021519318A5 (enExample) | ||
| AU2015296322B2 (en) | 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as CDK inhibitors and uses thereof | |
| JP2016504363A5 (enExample) | ||
| JP2021519291A5 (enExample) | ||
| KR102165113B1 (ko) | Ａ2ａ 길항제 성질을 갖는 헤테로비시클로-치환된-[1,2,4]트리아졸로[1,5-ｃ]퀴나졸린-5-아민 화합물 | |
| CN105294683B (zh) | Cdk类小分子抑制剂的化合物及其用途 | |
| JP2021528466A5 (enExample) | ||
| WO2024229317A1 (en) | Spiro-heterocyclic inhibitors of kras g12c mutant proteins and uses thereof | |
| JP2020522570A5 (enExample) | ||
| JP2014506929A5 (enExample) | ||
| JP2015508075A5 (enExample) | ||
| JP2013519707A5 (enExample) | ||
| WO2011035518A1 (zh) | 嘧啶衍生物和类似物及其制备方法和用途 | |
| US20110152243A1 (en) | Novel thienopyrrole compounds | |
| EP4237086A1 (en) | Heterocyclic spiro compounds and methods of use | |
| JP2009538896A5 (enExample) | ||
| RU2017141077A (ru) | Ингибитор некоторых протеинкиназ | |
| JP2022502424A5 (enExample) | ||
| JP2011500774A (ja) | Ｐｉ３ｋ阻害剤としてのチエノピリミジエン誘導体 | |
| RU2011109223A (ru) | ПРОИЗВОДНЫЕ 2-АЛКИЛ-6-ЦИКЛОАМИНО-3-(ПИРИДИН-4-ИЛ)ИМИДАЗОЛ[1,2-b]-ПИРИДАЗИНА, СПОСОБ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ ИХ В ТЕРАПИИ |